Earnings Call · Q2 FY2021·2021-08-05

Q2 21EPS 0.00%·Rev n/aQ1 21EPS -100.00%*·Rev n/aQ4 20EPS -75.00%·Rev n/aQ3 20EPS +12.50%·Rev n/a⚠ consensus missing

Theriva Biologics, Inc. TOVX

Vincent Perrone — Director of Corporate Development

Steven Shallcross — CEO and CFO

−5.0%1d on move date−5.1% vs SPY3d−9.2%5d−14.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TOVX calls or request research access.

More TOVX calls Browse calls Request research access